Artificial pancreas market seen doubling by 2033 as diabetes cases rise

The global market for artificial pancreas devices is projected to grow from $0.4 billion in 2023 to $0.8 billion by 2033 as diabetes prevalence rises worldwide. Demand is being driven by tighter glucose management needs, faster sensor and software advances, and broader regulatory support.

Why it matters: - Rising diabetes rates are increasing demand for automated glucose management tools that can reduce the burden of manual insulin dosing. - Artificial pancreas systems are designed to improve blood sugar control and lower the risk of hypoglycemia and hyperglycemia. - The market’s projected doubling by 2033 signals a larger shift toward personalized, connected diabetes care.

What happened: - Allied Market Research said the global artificial pancreas devices systems market was valued at $0.4 billion in 2023. - The market is projected to reach $0.8 billion by 2033. - The report forecasts an 8.8% compound annual growth rate from 2024 to 2033. - The report was published June 24, 2026, from Portland, Oregon. - The report includes a sample PDF report and a purchase inquiry page.

The details: - Artificial pancreas systems combine continuous glucose monitoring devices, insulin pumps and algorithms to automate blood glucose control. - The report says growing awareness of diabetes management is boosting demand for glucose monitoring tools. - Sedentary lifestyles, rising obesity rates and aging populations are contributing to more diabetes-related complications. - The systems use closed-loop insulin delivery to reduce manual intervention. - The report says technological advances in sensors, software algorithms, wireless connectivity and real-time analytics are improving accuracy and response times. - Mobile apps and cloud platforms allow patients and caregivers to track glucose levels, adjust settings and review trends remotely. - Pediatric patients and people needing round-the-clock monitoring are among the groups that can benefit most from remote access. - Interoperable devices are expanding access to personalized diabetes management systems. - Regulatory approvals and government programs, including subsidies and reimbursement policies in some countries, are supporting adoption. - Clinical studies showing safety, efficiency and reliability are increasing provider confidence. - Adoption is growing across hospitals, endocrinology clinics and homecare settings.

Between the lines: - The growth outlook reflects both medical need and a technology transition toward automated insulin delivery. - High device costs and limited awareness in underdeveloped regions could slow adoption in some markets. - Cybersecurity and data privacy concerns remain a barrier as more devices connect to apps and cloud systems. - Competition appears to be moving toward hybrid closed-loop and fully automated systems with more precise dosing. - Partnerships between technology firms and medical device companies are likely to keep improving machine learning capabilities.

What's next: - Ongoing clinical trials are expected to further support regulatory approvals. - Manufacturers are likely to keep pushing for more affordable and user-friendly systems. - Wider commercialization should follow if reimbursement support and clinical validation continue to expand. - Demand is expected to rise as diabetes cases continue to increase globally.

The bottom line: - Artificial pancreas systems are moving from niche technology toward a mainstream diabetes management category, with growth driven by clinical need, digital health upgrades and broader policy support.